Literature DB >> 26469248

Antemortem Prediction of Braak Stage.

Jesper O E Carlson1, Margaret Gatz, Nancy L Pedersen, Caroline Graff, Inger Nennesmo, Anna-Karin Lindström, Lotte Gerritsen.   

Abstract

We examined the extent to which tauopathy distribution, as determined by Braak staging, might be predicted by various risk factors in older individuals. The Swedish Twin Registry provided extensive information on neuropsychological function, lifestyle, and cardiovascular risk factors of 128 patients for whom autopsy data including Braak staging were available. Logistic regression was used to develop a prognostic model that targeted discrimination between Braak stages 0 to II and III to VI. The analysis showed that Braak stages III to VI were significantly predicted by having 1 or more APOE ε4 alleles, older age, high total cholesterol, absence of diabetes and cardiovascular disease, and poorer scores on the Wechsler Adult Intelligence Score Information test, verbal fluency, and recognition memory but better verbal recall. The algorithm predicted Braak stages III to VI well (receiver-operating characteristic area under curve, 0.897; 95% confidence interval, 0.842-0.951). Using a cutoff of 50% risk or more, the sensitivity was 85%, the specificity was 70%, and the negative predictive value was 69%. This study demonstrates that tauopathy distribution can be accurately predicted using a combination of antemortem patient data. These results provide further insight into tauopathy development and AD-related disease mechanisms and suggest a prognostic model that predicts the spread of neurofibrillary tangles above the transentorhinal stage.

Entities:  

Mesh:

Year:  2015        PMID: 26469248      PMCID: PMC4610255          DOI: 10.1097/NEN.0000000000000251

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  70 in total

1.  Prognosis and prognostic research: Developing a prognostic model.

Authors:  Patrick Royston; Karel G M Moons; Douglas G Altman; Yvonne Vergouwe
Journal:  BMJ       Date:  2009-03-31

Review 2.  Antidiabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer's disease.

Authors:  Kannayiram Alagiakrishnan; Sowndramalingam Sankaralingam; Mahua Ghosh; Laurie Mereu; Peter Senior
Journal:  Discov Med       Date:  2013-12       Impact factor: 2.970

3.  Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects. A retrospective postmortem immunocytochemical and histofluorescent study.

Authors:  J Heitner; D Dickson
Journal:  Neurology       Date:  1997-11       Impact factor: 9.910

Review 4.  Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature.

Authors:  Peter T Nelson; Irina Alafuzoff; Eileen H Bigio; Constantin Bouras; Heiko Braak; Nigel J Cairns; Rudolph J Castellani; Barbara J Crain; Peter Davies; Kelly Del Tredici; Charles Duyckaerts; Matthew P Frosch; Vahram Haroutunian; Patrick R Hof; Christine M Hulette; Bradley T Hyman; Takeshi Iwatsubo; Kurt A Jellinger; Gregory A Jicha; Enikö Kövari; Walter A Kukull; James B Leverenz; Seth Love; Ian R Mackenzie; David M Mann; Eliezer Masliah; Ann C McKee; Thomas J Montine; John C Morris; Julie A Schneider; Joshua A Sonnen; Dietmar R Thal; John Q Trojanowski; Juan C Troncoso; Thomas Wisniewski; Randall L Woltjer; Thomas G Beach
Journal:  J Neuropathol Exp Neurol       Date:  2012-05       Impact factor: 3.685

Review 5.  Neuropsychology of Alzheimer's disease.

Authors:  Jordi Peña-Casanova; Gonzalo Sánchez-Benavides; Susana de Sola; Rosa Maria Manero-Borrás; Marta Casals-Coll
Journal:  Arch Med Res       Date:  2012-10-13       Impact factor: 2.235

6.  Midlife and late-life obesity and the risk of dementia: cardiovascular health study.

Authors:  Annette L Fitzpatrick; Lewis H Kuller; Oscar L Lopez; Paula Diehr; Ellen S O'Meara; W T Longstreth; José A Luchsinger
Journal:  Arch Neurol       Date:  2009-03

7.  Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: findings from the Nun Study.

Authors:  Kathryn P Riley; David A Snowdon; William R Markesbery
Journal:  Ann Neurol       Date:  2002-05       Impact factor: 10.422

8.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.

Authors:  Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2006-08-12       Impact factor: 17.088

Review 9.  Treatment of vascular risk factors in patients with a diagnosis of Alzheimer's disease: a systematic review.

Authors:  Raffaella Valenti; Leonardo Pantoni; Hugh S Markus
Journal:  BMC Med       Date:  2014-11-11       Impact factor: 8.775

10.  Mid- and late-life diabetes in relation to the risk of dementia: a population-based twin study.

Authors:  Weili Xu; Chengxuan Qiu; Margaret Gatz; Nancy L Pedersen; Boo Johansson; Laura Fratiglioni
Journal:  Diabetes       Date:  2008-10-24       Impact factor: 9.461

View more
  4 in total

1.  Few serum proteins mediate APOE's association with dementia.

Authors:  Donald R Royall; Safa Al-Rubaye; Ram Bishnoi; Raymond F Palmer
Journal:  PLoS One       Date:  2017-03-14       Impact factor: 3.240

2.  Population-based analysis of pathological correlates of dementia in the oldest old.

Authors:  Maarit Tanskanen; Mira Mäkelä; Irma-Leena Notkola; Liisa Myllykangas; Sari Rastas; Minna Oinas; Perttu J Lindsberg; Tuomo Polvikoski; Pentti J Tienari; Anders Paetau
Journal:  Ann Clin Transl Neurol       Date:  2017-02-12       Impact factor: 4.511

3.  Vascular Lesions, APOE ε4, and Tau Pathology in Alzheimer Disease.

Authors:  Jodie B Nichols; Michael Malek-Ahmadi; Pierre N Tariot; Geidy E Serrano; Lucia I Sue; Thomas G Beach
Journal:  J Neuropathol Exp Neurol       Date:  2021-02-22       Impact factor: 3.685

4.  Mid to late-life scores of depression in the cognitively healthy are associated with cognitive status and Alzheimer's disease pathology at death.

Authors:  Andrew C Robinson; Federico Roncaroli; Yvonne S Davidson; James Minshull; Calvin Heal; Daniela Montaldi; Antony Payton; Michael A Horan; Neil Pendleton; David M A Mann
Journal:  Int J Geriatr Psychiatry       Date:  2020-11-20       Impact factor: 3.485

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.